New imaging method could predict how breast cancer responds to hormone therapy
NCT ID NCT02409316
First seen Jun 14, 2026 · Last updated Jun 14, 2026
Summary
This study tested a special PET scan called FES PET/CT to see if it could measure estrogen receptor activity in women with advanced breast cancer that had stopped responding to hormone therapy. The goal was to see if the scan could help predict how long the cancer would stay under control with a new treatment. Only 6 people were enrolled before the study ended early, so the results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania Hospital
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.